Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
View: Text | PDF
Research Article Angiogenesis

VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

  • Text
  • PDF
Abstract

Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.

Authors

Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi

×

Figure 8

Therapeutic VEGFA165 gene treatment attenuates reduction in strial vascular density and improves hearing sensitivity after acoustic trauma.

Options: View larger image (or click on image) Download as PowerPoint
Therapeutic VEGFA165 gene treatment attenuates reduction in strial vascu...
(A) Strial microvasculature labeled with lectin and EdU+ cells in control, 4 weeks after noise exposure (NE) without gene treatment, noise-exposed + control AAV1-null gene treatment, and noise-exposed + AAV1-VEGFA165 gene treatment 2 weeks after acoustic trauma groups. Arrows indicate vessel enlargement and shrinkage after noise exposure, and arrowheads show representative EdU+ pericytes, ECs, and an unidentified cell type in the stria. (B and C) Data analysis of EdU+ cells/vessel area and capillary density in control, NE, NE+AAV1 null (control); and NE+AAV1 VEGFA165 (n = 8 for each group, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 1-way ANOVA). (D) Hearing thresholds at different frequencies are significantly elevated after noise exposure but improved after delivery of the AAV1-VEGFA165 (n = 6 for each group, *P < 0.05, and **P < 0.01 by 1-way ANOVA). Data are presented as mean ± SEM. Scale bars: 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts